Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Mel Spivak who wrote (1321)	1/18/1999 2:37:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 1722

Mel, Actos is a TZD, as is WLA's Rezulin and SBH's Avandia. As you know, there have been liver problems associated with Rezulin. Avandia (and I believe Actos) are second generation TZDs and are effective at lower doses. Liver problems also appear to be reduced, although analysts expect Avandia and Actos to receive a TZD class label which would have the same warnings as is found on the most recent Rezulin label (and I suspect users would also be required to have liver function tests). The TZDs activate a hormone receptor PPARgamma, which forms a complex with another hormone receptor, RXRalpha which is activated by rexinoids being developed by LGND (in collaboration with LLY) and AGN (in collaboration with WLA). I have quite a bit of Rezulin and Avandia data linked to the Ligand Diabetes page at biocognizance.com